These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 34260531)
1. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy. Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531 [TBL] [Abstract][Full Text] [Related]
2. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M; Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675 [TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708 [TBL] [Abstract][Full Text] [Related]
4. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933 [TBL] [Abstract][Full Text] [Related]
5. QTc prolongation during antiviral therapy in two COVID-19 patients. Zhu S; Wang J; Wang Y; Chu J; Liu Y; Chen X; Chen X J Clin Pharm Ther; 2020 Oct; 45(5):1190-1193. PubMed ID: 32779770 [TBL] [Abstract][Full Text] [Related]
6. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19. Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612 [TBL] [Abstract][Full Text] [Related]
7. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine. Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617 [TBL] [Abstract][Full Text] [Related]
8. Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019. Uğurlu Ilgın B; Akbulut Koyuncu İM; Kızıltunç E Anatol J Cardiol; 2021 Mar; 25(3):184-190. PubMed ID: 33690133 [TBL] [Abstract][Full Text] [Related]
9. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252 [TBL] [Abstract][Full Text] [Related]
10. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Sarayani A; Cicali B; Henriksen CH; Brown JD Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397 [TBL] [Abstract][Full Text] [Related]
11. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991 [TBL] [Abstract][Full Text] [Related]
12. Effects of hydroxychloroquine treatment on QT interval. Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165 [TBL] [Abstract][Full Text] [Related]
13. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD; Therapie; 2020; 75(4):371-379. PubMed ID: 32418730 [TBL] [Abstract][Full Text] [Related]
14. QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection. El Nekidy WS; Almuti K; ElRefaei H; Atallah B; Mohammad LM; AlMahmeed W; Badr M; Abdallah K; Hamed F; Mallat J J Cardiovasc Pharmacol Ther; 2022; 27():10742484211069479. PubMed ID: 35006023 [TBL] [Abstract][Full Text] [Related]
15. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554 [TBL] [Abstract][Full Text] [Related]
16. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Xin S; Cheng X; Zhu B; Liao X; Yang F; Song L; Shi Y; Guan X; Su R; Wang J; Xing L; Xu X; Jin L; Liu Y; Zhou W; Zhang D; Liang L; Yu Y; Yu R Biomed Pharmacother; 2020 Sep; 129():110500. PubMed ID: 32768975 [TBL] [Abstract][Full Text] [Related]
17. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348 [TBL] [Abstract][Full Text] [Related]
18. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098 [TBL] [Abstract][Full Text] [Related]
19. Prevalence, Outcomes, and Predictors of Prolonged Corrected QT Interval in Hydroxychloroquine-Naïve Hospitalized COVID-19 Patients. Gupta P; Gupta A; Gupta K; Bansal S; Sharma M; Balakrishnan I Cardiovasc Toxicol; 2024 Oct; 24(10):1053-1066. PubMed ID: 38954228 [TBL] [Abstract][Full Text] [Related]